Please try another search
For the fiscal year ended 31 December 2010, Plus Therapeutics Inc revenues decreased 28% to $10.6M. Net loss increased 18% to $27.5M. Revenues reflect Development, Related Party decrease of 76% to $2.1M, Related Party Sales decrease of less than 1% to $590K. Higher net loss reflects Sales/Marketing increase of 68% to $11M (expense), General/Admin. increase of 21% to $12.6M (expense), Interest Expense increase of 44% to $2.1M (expense).
Period Ending: | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 |
---|---|---|---|---|
Total Revenue | 2.54 | 1.58 | 2.1 | 4.41 |
Gross Profit | 1.36 | 0.66 | 1.22 | 3.48 |
Operating Income | -8.61 | -9.59 | -5.04 | -2.08 |
Net Income | -9.25 | -10.42 | -5.38 | -2.45 |
Period Ending: | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 |
---|---|---|---|---|
Total Assets | 66.35 | 43.38 | 50.49 | 35.45 |
Total Liabilities | 43.47 | 38.86 | 36.39 | 22.71 |
Total Equity | 22.87 | 4.52 | 14.1 | 12.74 |
Period Ending: | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -23.57 | -18.8 | -11.9 | -7.4 |
Cash From Investing Activities | -1.29 | -1.15 | -0.68 | -0.19 |
Cash From Financing Activities | 64.68 | 37.83 | 37.83 | 17.43 |
Net Change in Cash | 39.81 | 17.88 | 25.25 | 9.83 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review